Related Experiment Videos
Progestin (norethisterone)-induced genetic damage in mouse bone marrow
1Department of Biosciences, Mangalore University, India.
Mutation Research
|August 1, 1993
Summary
Primolut-N (norethisterone) showed genotoxic effects, significantly increasing chromosomal aberrations in mouse bone marrow at higher doses. However, it did not significantly elevate micronuclei, suggesting a complex genotoxic profile.
Area of Science:
- Pharmacology
- Toxicology
- Genetics
Background:
- Norethisterone, a synthetic progestogen, is widely used in hormonal therapies.
- Assessing the in vivo genotoxicity of commonly used pharmaceuticals is crucial for public health.
- Previous studies on norethisterone's genotoxicity have yielded varied results.
Purpose of the Study:
- To evaluate the in vivo genotoxic potential of Primolut-N (norethisterone) on bone marrow cells of Swiss albino mice.
- To determine dose-dependent and time-dependent genotoxic effects.
- To compare results from two distinct genotoxicity assays.
Main Methods:
- In vivo genotoxicity assessment using Swiss albino mice.
- Chromosomal aberration assay in bone marrow cells.
- Micronucleus test in bone marrow erythrocytes.
Main Results:
- A statistically significant increase in chromosomal aberrations was observed at Primolut-N doses greater than or equal to 3.0 mg/kg/day.
- The highest frequency of chromosomal aberrations occurred at 24 hours post-treatment, decreasing over time.
- No significant increase in micronuclei was detected in bone marrow erythrocytes at any tested dose or time interval.
Conclusions:
- Primolut-N exhibits genotoxic activity, evidenced by the induction of chromosomal aberrations in mouse bone marrow.
- The absence of a significant micronucleus response suggests that the genotoxic mechanism may not involve clastogenicity or aneugenicity leading to micronuclei formation.
- Further investigation is warranted to fully elucidate the genotoxic profile and potential risks associated with norethisterone use.